SARCOMATRIX

With over 30 years experience developing products in the life sciences industry, David has worked in building biotechnology companies and supporting their initial fundraising efforts, growth and commercialization. He has previously held senior positions at Amgen, AstraZeneca, Gilead and Alexion. He will be providing Form C sign-off as the Company's Principal Accounting Officer.

I'm an economist who is valued as a decision-support partner with company founders, co-founders, and academic professors. By providing distinct analysis, data sourcing, market research, financial modeling, business acumen and critical decision-making, I am able to refine business models and value propositions into efficient operational practices to accelerate commercialization. Driven by opportunity to improve global health, I have partnered with several firms to bridge early stage development processes into real world applications.

Dr. Ryan Wuebbles received his PhD in 2009 from the University of Illinois. He been involved in researching muscular dystrophy causes and therapeutics for over 20 years, including 15 years working with Dr. Burkin developing the Laminin and small molecule programs.

Dean Burkin is a Professor of Pharmacology and Interim Chair of Physiology and Cell Biology at the University of Nevada, Reno. The primary goal of my research program is to understand the role integrin receptors and the extracellular matrix play in muscle disease and develop novel therapeutics.

"Michael J. M. Hitchcock, Ph.D. (Mick) is currently Adjunct Professor of Microbiology at University of Nevada, Reno (UNR) Medical School and a member of the Advisory Boards for the UNR Colleges of Science and Business. He is also a Trustee Emeritus of the UNR Foundation Board, and was Chair in 2020. In addition he serves on the Board of Directors for 3 small companies (Biomea Fusion, Renogenyx and ClickBio) and a pro-science information organization (American Council for Science & Health). His career in pharmaceutical research & development spanned 40 years, initially with Bristol-Myers Squibb for 12 years. He joined Gilead Sciences, Inc. in 1993 and helped it grow from only 100 employees and no products or revenues to >20,000 employees and >$20B annual revenue. Over 27 years, he was Vice President for project and portfolio management, alliance management, strategic planning, medical affairs, specific areas of research, and then Senior Advisor. During his career, he was involved in the development and commercialization of a number of anti-infective agents, primarily drugs for treatment of viral diseases. This included the first single pill containing 3 drugs (ATRIPLA) that can be taken once daily to simplify treatment of HIV; and that led to additional single tablet regimens that are the standard of care today. Dr. Hitchcock received his Ph.D. in microbiology from the University of Melbourne, Australia and B.Sc. and M.Sc. degrees in biochemistry from the University of Manchester Institute of Science and Technology, England. He did post-doctoral research at Georgetown University and NIH prior to joining industry.